Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

This study is currently recruiting participants.

Study NCT00049023 Information provided by National Cancer Institute (NCI)

First Received: November 12, 2002 Last Updated: February 6, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Neuroblastoma
Pheochromocytoma
Sarcoma

Additional conditions recognized in this trial

Adenoma, Islet Cell
Carcinoid Tumor
Central Nervous System Neoplasms
Gastrointestinal Neoplasms
Malignant Carcinoid Syndrome
Nervous System Neoplasms
Neuroectodermal Tumors, Primitive, Peripheral

Interventions listed in this trial

yttrium Y 90-edotreotide

Additional drug interventions recognized in this trial

Octreotide

More general drug interventions related to this trial

Antineoplastic Agents
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses

Sponsors listed in this trial

Holden Comprehensive Cancer Center
National Cancer Institute (NCI)

Back to top of Main Content